Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study on the Efficacy and Safety of Neoadjuvant Radiotherapy Combined With Tislelizumab, Liposomal Irinotecan, and Capecitabine in the Treatment of pMMR Locally Advanced Rectal Adenocarcinoma With Low Rectal Involvement

NCT07104604 is registered in ClinicalTrials.gov with Affiliated Cancer Hospital of Shantou University Medical College as lead sponsor.

NCT NCT07104604
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07104604 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study on the Efficacy and Safety of Neoadjuvant Radiotherapy Combined With Tislelizumab, Liposomal Irinotecan, and Capecitabine in the Treatment of pMMR Locally Advanced Rectal Adenocarcinoma With Low Rectal Involvement
Lead sponsor
Affiliated Cancer Hospital of Shantou University Medical College
Phase
Phase 2
Overall status
Recruiting
Start date
October 20, 2025
Completion date
June 30, 2027
Enrollment
51 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

rectal cancer